These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 19999637

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?
    Joseph JN, Deaton D, Ehsan H, Bonanno MA.
    J Health Life Sci Law; 2009 Jan; 2(2):73-108. PubMed ID: 19288889
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Proposed rule.
    Fed Regist; 1998 Jun 08; 63(109):31143-61. PubMed ID: 10180130
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep 05; 62(172):46875-6. PubMed ID: 10173286
    [Abstract] [Full Text] [Related]

  • 34. FDA Modernization Act: implications for oncology.
    Morris L.
    Oncology (Williston Park); 1998 Nov 05; 12(11A):139-41. PubMed ID: 10028506
    [Abstract] [Full Text] [Related]

  • 35. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E, Allen PJ.
    Pediatr Nurs; 2007 Nov 05; 33(1):64-70. PubMed ID: 17411005
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
    Hall RF, Sobotka E.
    Food Drug Law J; 2007 Nov 05; 62(1):1-48. PubMed ID: 17444025
    [No Abstract] [Full Text] [Related]

  • 38. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul 05; 98(1):143-5. PubMed ID: 8668390
    [Abstract] [Full Text] [Related]

  • 39. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use.
    Meadows WA, Hollowell BD.
    Int J Impot Res; 2008 Jul 05; 20(2):135-44. PubMed ID: 18004389
    [Abstract] [Full Text] [Related]

  • 40. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB, Kennedy EM.
    Health Aff (Millwood); 2007 Jul 05; 26(3):678-80. PubMed ID: 17485743
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.